The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Abstract
BACKGROUND: We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated advanced esophagogastric cancer. METHODS: In a two-by-two design, we randomly assigned 1002 patients to receive triplet therapy with epirubicin and cisplatin plus either fluorouracil (ECF) or capecitabine (ECX) or triplet therapy with epirubicin and oxaliplatin plus either fluorouracil (EOF) or capecitabine (EOX). The primary end point was noninferiority in overall survival for the triplet therapies containing capecitabine as compared with fluorouracil and for those containing oxaliplatin as compared with cisplatin. RESULTS: For the capecitabine-fluorouracil comparison, the hazard ratio for death in the capecitabine group was 0.86 (95% confidence interval [CI], 0.80 to 0.99); for the oxaliplatin-cisplatin comparison, the hazard ratio for the oxaliplatin group was 0.92 (95% CI, 0.80 to 1.10). The upper limit of the confidence intervals for both hazard ratios excluded the predefined noninferiority margin of 1.23. Median survival times in the ECF, ECX, EOF, and EOX groups were 9.9 months, 9.9 months, 9.3 months, and 11.2 months, respectively; survival rates at 1 year were 37.7%, 40.8%, 40.4%, and 46.8%, respectively. In the secondary analysis, overall survival was longer with EOX than with ECF, with a hazard ratio for death of 0.80 in the EOX group (95% CI, 0.66 to 0.97; P=0.02). Progression-free survival and response rates did not differ significantly among the regimens. Toxic effects of capecitabine and fluorouracil were similar. As compared with cisplatin, oxaliplatin was associated with lower incidences of grade 3 or 4 neutropenia, alopecia, renal toxicity, and thromboembolism but with slightly higher incidences of grade 3 or 4 diarrhea and neuropathy. CONCLUSIONS: Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer. (Current Controlled Trials number, ISRCTN51678883 [controlled-trials.com].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Self-citationVan Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0245 · Cited by 1,171
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Cited by
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00797-2 · Cited by 3,041
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Japanese Gastric Cancer Association (2017) · Gastric Cancer · doi:10.1007/s10120-016-0622-4 · Cited by 2,429
Pennathur, A., Gibson, M. K., Jobe, B. A., & Luketich, J. D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60643-6 · Cited by 2,390
Ychou, M., Boige, V., Pignon, J.-P., Conroy, T., Bouché, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J.-M., Saint-Aubert, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0597 · Cited by 2,086
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847
Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K., & Prenen, H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30354-3 · Cited by 1,793
Japanese gastric cancer treatment guidelines 2018 (5th edition)
Japanese Gastric Cancer Association (2021) · Gastric Cancer · doi:10.1007/s10120-020-01042-y · Cited by 1,749
Current treatment and recent progress in gastric cancer
Joshi, S. S., & Badgwell, B. D. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21657 · Cited by 1,677
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Smyth, E. C., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw350 · Cited by 1,555
Self-citationGastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., Vogel, A., & Smyth, E. C. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.004 · Cited by 1,503
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Okines, A., Verheij, M., Allum, W., Cunningham, D., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq164 · Cited by 1,300
Self-citationChemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Shitara, K., Van Cutsem, E., Bang, Y.-J., Fuchs, C., Wyrwicz, L., Lee, K.-W., Kudaba, I., Garrido, M., Chung, H. C., Lee, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3370 · Cited by 1,141
Lagergren, J., Smyth, E., Cunningham, D., & Lagergren, P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31462-9 · Cited by 1,141
Self-citationOhtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lordick, F., Mariette, C., Haustermans, K., Obermannová, R., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw329 · Cited by 1,098
Aapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., Denlinger, C. S., Enzinger, P. C., Fanta, P., Farjah, F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0033 · Cited by 1,059
Smyth, E. C., Lagergren, J., Fitzgerald, R. C., Lordick, F., Shah, M. A., Lagergren, P., & Cunningham, D. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.48 · Cited by 1,012
Self-citationLi, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., Liu, W., Tong, J., Liu, Y., Xu, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5995 · Cited by 972
Hartgrink, H. H., Jansen, E. P., van Grieken, N. C., & van de Velde, C. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60617-6 · Cited by 875
Lordick, F., Kang, Y.-K., Chung, H.-C., Salman, P., Oh, S. C., Bodoky, G., Kurteva, G., Volovat, C., Moiseyenko, V. M., Gorbunova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70102-5 · Cited by 833
Wang, F., Shen, L., Li, J., Zhou, Z., Liang, H., Zhang, X., Tang, L., Xin, Y., Jin, J., Zhang, Y., et al. (2019) · Cancer Communications · doi:10.1186/s40880-019-0349-9 · Cited by 810
Guidelines for the management of oesophageal and gastric cancer
Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., Wong, R., & On behalf of the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, T. B. S. O. G. A. T. B. A. O. S. O. (2011) · Gut · doi:10.1136/gut.2010.228254 · Cited by 793
Self-citationGastric cancer: a comprehensive review of current and future treatment strategies
Sexton, R. E., Al Hallak, M. N., Diab, M., & Azmi, A. S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09925-3 · Cited by 772
Kang, Y.-K., Kang, W.-K., Shin, D.-B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn717 · Cited by 764
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A. F. C., Wotherspoon, A., Saffery, C., Middleton, G., Wadsley, J., Ferry, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70096-2 · Cited by 725
Self-citationFujitani, K., Yang, H.-K., Mizusawa, J., Kim, Y.-W., Terashima, M., Han, S.-U., Iwasaki, Y., Hyung, W. J., Takagane, A., Park, D. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00553-7 · Cited by 712
Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment
Abdol Razak, N., Jones, G., Bhandari, M., Berndt, M., & Metharom, P. (2018) · Cancers · doi:10.3390/cancers10100380 · Cited by 631
Hecht, J. R., Bang, Y.-J., Qin, S. K., Chung, H. C., Xu, J. M., Park, J. O., Jeziorski, K., Shparyk, Y., Hoff, P. M., Sobrero, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6598 · Cited by 624
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624
Orditura, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1635 · Cited by 623
Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G., & Reichardt, P. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.002 · Cited by 612
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Van Cutsem, E., Bang, Y.-J., Feng-yi, F., Xu, J. M., Lee, K.-W., Jiao, S.-C., Chong, J. L., López-Sanchez, R. I., Price, T., Gladkov, O., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-014-0402-y · Cited by 608
Boku, N., Yamamoto, S., Fukuda, H., Shirao, K., Doi, T., Sawaki, A., Koizumi, W., Saito, H., Yamaguchi, K., Takiuchi, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70259-1 · Cited by 586
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Cats, A., Jansen, E. P. M., van Grieken, N. C. T., Sikorska, K., Lind, P., Nordsmark, M., Meershoek-Klein Kranenbarg, E., Boot, H., Trip, A. K., Swellengrebel, H. A. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30132-3 · Cited by 561
Advanced gastric cancer: Current treatment landscape and future perspectives
Digklia, A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2403 · Cited by 560
Ajani, J. A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., Vynnychenko, I., Garin, A., Lang, I., & Falcon, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4706 · Cited by 550
Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5805 · Cited by 541
Smyth, E. C., Wotherspoon, A., Peckitt, C., Gonzalez, D., Hulkki-Wilson, S., Eltahir, Z., Fassan, M., Rugge, M., Valeri, N., Okines, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6762 · Cited by 521
Self-citationSimkens, L. H. J., van Tinteren, H., May, A., ten Tije, A. J., Creemers, G.-J. M., Loosveld, O. J. L., de Jongh, F. E., Erdkamp, F. L. G., Erjavec, Z., van der Torren, A. M. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62004-3 · Cited by 517
Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2014.07.030 · Cited by 481
Chemotherapy for advanced gastric cancer
Wagner, A. D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., & Fleig, W. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub3 · Cited by 472
Management of gastric cancer in Asia: resource-stratified guidelines
Shen, L., Shan, Y.-S., Hu, H.-M., Price, T. J., Sirohi, B., Yeh, K.-H., Yang, Y.-H., Sano, T., Yang, H.-K., Zhang, X., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70436-4 · Cited by 461
Northover, J., Glynne-Jones, R., Sebag-Montefiore, D., James, R., Meadows, H., Wan, S., Jitlal, M., & Ledermann, J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605605 · Cited by 436
Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy
Alcindor, T., & Beauger, N. (2011) · Current Oncology · doi:10.3747/co.v18i1.708 · Cited by 432
the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Secrier, M., Li, X., de Silva, N., Eldridge, M. D., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O'Donovan, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 405
Sundar, R., Nakayama, I., Markar, S. R., Shitara, K., van Laarhoven, H. W. M., Janjigian, Y. Y., & Smyth, E. C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00052-2 · Cited by 393
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach
Guideline Committee of the Korean Gastric Cancer Association (KGCA), D. W. G. &. R. P. (2019) · Journal of Gastric Cancer · doi:10.5230/jgc.2019.19.e8 · Cited by 392
Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., Vynnychenko, I., Dudov, A., Bazin, I., Bondarenko, I., Melichar, B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.005 · Cited by 383
Crosby, T., Hurt, C. N., Falk, S., Gollins, S., Mukherjee, S., Staffurth, J., Ray, R., Bashir, N., Bridgewater, J. A., Geh, J. I., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70136-0 · Cited by 381
Self-citationCatalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F., & Van Cutsem, E. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.004 · Cited by 365
Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu159 · Cited by 355
Ishigami, H., Fujiwara, Y., Fukushima, R., Nashimoto, A., Yabusaki, H., Imano, M., Imamoto, H., Kodera, Y., Uenosono, Y., Amagai, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8613 · Cited by 353
Yoshida, K., Yamaguchi, K., Okumura, N., Tanahashi, T., & Kodera, Y. (2016) · Gastric Cancer · doi:10.1007/s10120-015-0575-z · Cited by 350
Current developments in gastric cancer: from molecular profiling to treatment strategy
Alsina, M., Arrazubi, V., Diez, M., & Tabernero, J. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00703-w · Cited by 350
Catenacci, D. V. T., Tebbutt, N. C., Davidenko, I., Murad, A. M., Al-Batran, S.-E., Ilson, D. H., Tjulandin, S., Gotovkin, E., Karaszewska, B., Bondarenko, I., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30566-1 · Cited by 348
Self-citationEsophageal and Esophagogastric Junction Cancers
Ajani, J. A., Barthel, J. S., Bentrem, D. J., D'Amico, T. A., Das, P., Denlinger, C. S., Fuchs, C. S., Gerdes, H., Glasgow, R. E., Hayman, J. A., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0072 · Cited by 331
Coccolini, F. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6979 · Cited by 325
Dutton, S. J., Ferry, D. R., Blazeby, J. M., Abbas, H., Dahle-Smith, A., Mansoor, W., Thompson, J., Harrison, M., Chatterjee, A., Falk, S., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70024-5 · Cited by 324
Boku, N., Ryu, M.-H., Kato, K., Chung, H. C., Minashi, K., Lee, K.-W., Cho, H., Kang, W. K., Komatsu, Y., Tsuda, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy540 · Cited by 312
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Burgess, J., Ferdousi, M., Gosal, D., Boon, C., Matsumoto, K., Marshall, A., Mak, T., Marshall, A., Frank, B., Malik, R. A., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00168-y · Cited by 306
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt344 · Cited by 303
Self-citationMuro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B. C., Nor, I. M., Ng, M., Chen, L. T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy498 · Cited by 289
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Kim, T.-H., Kim, I.-H., Kang, S. J., Choi, M., Kim, B.-H., Eom, B. W., Kim, B. J., Min, B.-H., Choi, C. I., Shin, C. M., et al. (2023) · Journal of Gastric Cancer · doi:10.5230/jgc.2023.23.e11 · Cited by 288
S3-Leitlinie „Magenkarzinom” -
Moehler, M., Al-Batran, S.-E., Andus, T., Anthuber, M., Arends, J., Arnold, D., Aust, D., Baier, P., Baretton, G., Bernhardt, J., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0031-1273201 · Cited by 283
Kawazoe, A., Fukuoka, S., Nakamura, Y., Kuboki, Y., Wakabayashi, M., Nomura, S., Mikamoto, Y., Shima, H., Fujishiro, N., Higuchi, T., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30271-0 · Cited by 269
Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.04.013 · Cited by 269
Iveson, T., Donehower, R. C., Davidenko, I., Tjulandin, S., Deptala, A., Harrison, M., Nirni, S., Lakshmaiah, K., Thomas, A., Jiang, Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70023-3 · Cited by 265
Self-citationGuimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., André, T., Gornet, J.-M., Aparicio, T., Nguyen, S., Azzedine, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1011 · Cited by 263
Myint, K., Biswas, R., Li, Y., Jong, N., Jamieson, S., Liu, J., Han, C., Squire, C., Merien, F., Lu, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38667-8 · Cited by 262
Okines, A. F. C., Norman, A. R., McCloud, P., Kang, Y.-K., & Cunningham, D. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp047 · Cited by 258
Self-citationKato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9709-2 · Cited by 237
S-1: a promising new oral fluoropyrimidine derivative
Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902729412 · Cited by 101
Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr031 · Cited by 90
Self-citationLi, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80
SASADA, S., MIYATA, Y., TSUTANI, Y., TSUYAMA, N., MASUJIMA, T., HIHARA, J., & OKADA, M. (2013) · Oncology Reports · doi:10.3892/or.2012.2182 · Cited by 41
Metadata
- Authors
- Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-01-03
- Volume
- 358
- Issue
- 1
- Pages
- 36-46
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2128328462
- Cited by
- 2,285
- References
- 29
- FWCI
- 122.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.